Von Seggern Christopher 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 15, 2021
Insider Transaction Report
Form 4
Von Seggern Christopher
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-03-12+60,000→ 60,000 totalExercise: $20.55Exp: 2031-03-11→ Common Shares (60,000 underlying)
Footnotes (1)
- [F1]Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.